Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma

被引:16
作者
Balzarotti, M
Santoro, A
Tondini, C
Fornier, M
Bonadonna, G
机构
[1] Division of Medical Oncology, Istituto Nazionale Tumori, Milan
[2] Division of Medical Oncology, Istituto Nazionale Tumori, 20133, Milan
关键词
non-Hodgkin's lymphoma; salvage therapy; vinorelbine;
D O I
10.1093/oxfordjournals.annonc.a010802
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To assess the activity of single agent vinorelbine in pretreated non Hodgkin's lymphoma. Patients and methods: Twenty-three pretreated patients with non-Hodgkin's lymphoma (14 intermediate-high grade, nine low-grade) were treated with vinorelbine 30 mg/m(2)/week for six months or up to four doses after achieving CR. Results: Among 13 evaluable patients with intermediate-high grade lymphoma, three obtained CR and three PR, for an overall response rate of 46% (95% CI: 19%-75%). Median duration of response was six months. Otherwise, vinorelbine did not show any significant activity in chemotherapy-refractory low-grade non-Hodgkin's lymphoma. Toxicity was acceptable, and the drug was well-tolerated even in elderly patients. Conclusions: The good activity and tolerability of vinorelbine in relapsed intermediate-high grade lymphoma suggest its inclusion in first-line regimens, especially in elderly patients.
引用
收藏
页码:970 / 972
页数:3
相关论文
共 9 条
  • [1] CONNOY T, 1996, J CLIN ONCOL, V16, P164
  • [2] VINORELBINE - AN ACTIVE-DRUG FOR THE MANAGEMENT OF PATIENTS WITH HEAVILY PRETREATED HODGKINS-DISEASE
    DEVIZZI, L
    SANTORO, A
    BONFANTE, V
    VIVIANI, S
    BALZARINI, L
    VALAGUSSA, P
    BONADONNA, G
    [J]. ANNALS OF ONCOLOGY, 1994, 5 (09) : 817 - 820
  • [3] EGHBALI H, 1991, NAVELBINE ( VINORELBINE ) - UPDATE AND NEW TRADE, P253
  • [4] LECHEVALIER T, 1994, J CLIN ONCOL, V12, P200
  • [5] AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS COMPARED WITH SALVAGE CHEMOTHERAPY IN RELAPSES OF CHEMOTHERAPY-SENSITIVE NON-HODGKINS-LYMPHOMA
    PHILIP, T
    GUGLIELMI, C
    HAGENBEEK, A
    SOMERS, R
    VANDERLELIE, H
    BRON, D
    SONNEVELD, P
    GISSELBRECHT, C
    CAHN, JY
    HAROUSSEAU, JL
    COIFFIER, B
    BIRON, P
    MANDELLI, F
    CHAUVIN, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) : 1540 - 1545
  • [6] A PHASE-II TRIAL OF MESNA IFOSFAMIDE, MITOXANTRONE AND ETOPOSIDE FOR REFRACTORY LYMPHOMAS
    RODRIGUEZ, MA
    CABANILLAS, FC
    HAGEMEISTER, FB
    MCLAUGHLIN, P
    ROMAGUERA, JE
    SWAN, F
    VELASQUEZ, W
    [J]. ANNALS OF ONCOLOGY, 1995, 6 (06) : 609 - 611
  • [7] ESHAP - AN EFFECTIVE CHEMOTHERAPY REGIMEN IN REFRACTORY AND RELAPSING LYMPHOMA - A 4-YEAR FOLLOW-UP-STUDY
    VELASQUEZ, WS
    MCLAUGHLIN, P
    TUCKER, S
    HAGEMEISTER, FB
    SWAN, F
    RODRIGUEZ, MA
    ROMAGUERA, J
    RUBENSTEIN, E
    CABANILLAS, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) : 1169 - 1176
  • [8] VELASQUEZ WS, 1988, BLOOD, V71, P117
  • [9] INTRAVENOUS VINORELBINE AS FIRST-LINE AND 2ND-LINE THERAPY IN ADVANCED BREAST-CANCER
    WEBER, BL
    VOGEL, C
    JONES, S
    HARVEY, H
    HUTCHINS, L
    BIGLEY, J
    HOHNEKER, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) : 2722 - 2730